Interestingly, quinidine, which acts as a non competitive antagonist—strychnine has a similar effect on muscle nAChR [109]—is used nowadays to treat patients with slow-channel congenital myasthenia. The gene discussed is CHRNA4; the disease is congenital myasthenic syndrome.